10357-07-0 Usage
Uses
Used in Cancer Therapy:
N4-Benzoyl-5-fluorocytosine is used as an anticancer agent for its potential to disrupt DNA replication and protein synthesis in cancer cells. It has been investigated for its efficacy against various types of cancer, with research highlighting its promising anticancer activity.
Used in Antiviral Treatment:
In the field of antiviral treatment, N4-Benzoyl-5-fluorocytosine is utilized for its ability to interfere with viral replication processes. Its antiviral properties make it a potential candidate for the development of treatments against viral infections.
Used in Pharmaceutical Research and Development:
N4-Benzoyl-5-fluorocytosine is used as a subject of research in pharmaceutical development, with ongoing studies aimed at understanding its mechanism of action and optimizing its potential for clinical use. This includes exploring its synergistic effects with other drugs and developing drug delivery systems to enhance its bioavailability and therapeutic outcomes.
Used in Drug Synthesis:
As a derivative of cytosine, N4-Benzoyl-5-fluorocytosine is also used in the synthesis of other pharmaceutical compounds, leveraging its unique chemical properties to create new molecules with potential therapeutic applications.
Check Digit Verification of cas no
The CAS Registry Mumber 10357-07-0 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 1,0,3,5 and 7 respectively; the second part has 2 digits, 0 and 7 respectively.
Calculate Digit Verification of CAS Registry Number 10357-07:
(7*1)+(6*0)+(5*3)+(4*5)+(3*7)+(2*0)+(1*7)=70
70 % 10 = 0
So 10357-07-0 is a valid CAS Registry Number.
InChI:InChI=1/C11H8FN3O2/c12-8-6-13-11(17)15-9(8)14-10(16)7-4-2-1-3-5-7/h1-6H,(H2,13,14,15,16,17)
10357-07-0Relevant academic research and scientific papers
N -Glycosylation with sulfoxide donors for the synthesis of peptidonucleosides
Beau, Jean-Marie,Beretta, Margaux,Dr?ge, Thomas,Es-Sayed, Mazen,Nicolas, Lionel,Norsikian, Stéphanie,Rouchaud, Emilie,Vors, Jean-Pierre
supporting information, p. 4285 - 4291 (2021/05/31)
The synthesis of glycopyranosyl nucleosides modified in the sugar moiety has been less frequently explored, notably because of the lack of a reliable method to glycosylate pyrimidine bases. Herein we report a solution in the context of the synthesis of peptidonucleosides. They were obtained after glycosylation of different pyrimidine nucleobases with glucopyranosyl donors carrying an azide group at the C4 position. A methodological study involving different anomeric leaving groups (acetate, phenylsulfoxide and ortho-hexynylbenzoate) showed that a sulfoxide donor in combination with trimethylsilyl triflate as the promoter led to the best yields.
Highly stereoselective synthesis of lamivudine (3TC) and emtricitabine (FTC) by a novel N -glycosidation procedure
Caso, Maria Federica,Dalonzo, Daniele,Derrico, Stefano,Palumbo, Giovanni,Guaragna, Annalisa
supporting information, p. 2626 - 2629 (2015/06/16)
The combined use of silanes (Et3SiH or PMHS) and I2 as novel N-glycosidation reagents for the synthesis of bioactive oxathiolane nucleosides 3TC and FTC is reported. Both systems (working as anhydrous HI sources) were devised to act as substrate activators and N-glycosidation promoters. Excellent results in terms of chemical efficiency and stereoselectivity of the reactions were obtained; surprisingly, the nature of the protective group at the N4 position of (fluoro)cytosine additionally influenced the stereochemical reaction outcome.
